Purpose: Anticonvulsant drugs are effective in the treatment of chronic neuropathic pain but were not, until recently, thought to be useful in more acute conditions such as postoperative pain. However, similar to nerve injury, surgical tissue injury is known to produce neuroplastic changes leading to spinal sensitization and the expression of stimulus-evoked hyperalgesia and allodynia. Pharmacological effects of anticonvulsant drugs which may be important in the modulation of these postoperative neural changes include suppression of sodium channel, calcium channel and glutamate receptor activity at peripheral, spinal and supraspinal sites. The purpose of this article is to review preclinical evidence and clinical trial data describing the efficacy and safety of anticonvulsant drugs in the setting of postoperative pain management. Source: A Medline search was performed to retrieve available literature on the basic and clinical pharmacology of anticonvulsant drugs as they pertain to postoperative pain management. Principal findings: Numerous laboratory studies have described analgesic effects of different anticonvulsant drugs in experimental pain models. Furthermore, several recent clinical trials have shown that anticonvulsants may reduce spontaneous and movement-evoked pain, as well as decrease opioid requirements postoperatively. Some early findings suggest further that anticonvulsant drugs may alleviate postoperative anxiety, accelerate postoperative functional recovery and reduce chronic postsurgical pain. Conclusion: Given the incomplete efficacy of currently available non-opioid analgesics, and the identified benefits of opioid sparing, anticonvulsant medications may be useful adjuncts for postoperative analgesia. Further research in this field is warranted. 
O VER 40 million surgeries per year are performed in North America, including major procedures to treat cancer, cardiovascular, traumatic and degenerative conditions. 1 Postoperative care involves pain and symptom management, 2 prevention and treatment of postoperative complications 3 and recovery of preoperative function. 4 While postoperative pain at rest has long been recognized to be responsive to opioid therapy, 5 attention has shifted over the past two decades to the understanding and treatment of movement-evoked or dynamic pain. 6 Postoperative pain evoked by movement is considerably less responsive to opioids. 5 Perhaps more importantly, poorly controlled movement-evoked pain has been related to postoperative pulmonary, 7 cardiac 8 and thromboembolic 9 complications which can be both devastating to the patient and costly to the healthcare system. 10, 11 With the early discovery that anticonvulsant drugs could be useful in treating trigeminal neuralgia, 12, 13 neurophysiological concepts evolved which make some associations between epilepsy and neuropathic pain. 14 Similarly, some parallels can be drawn between postsurgical and neuropathic pain. Since stimuli which evoke pain after surgery are often mild in intensity or altogether innocuous, movement-evoked pain is actually a manifestation of hyperalgesia or allodynia. 15 This observation highlights some common pathophysiological, clinical and pharmacological features that postoperative pain shares with neuropathic pain. Although surgical nerve injury is indeed one cause of neuropathic pain, initiation mechanisms of postsurgical and neuropathic pain are usually different. However, perpetuation and maintenance of neuropathic and postsurgical pain both often involve sensitization of primary afferent and second-order dorsal horn neurons. 16, 17 Furthermore, excitatory amino acids such as glutamate play a major role in both of these conditions, and both neuropathic and postsurgical pain are often manifest by hyperalgesia and allodynia at or near the affected sites. 18 There is also some overlap with respect to treatment responses. Non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen are effective for postoperative 19, 20 but not neuropathic pain 21 , whereas opioids 22, 23 and local anesthetics 24, 25 may be helpful in both conditions. The purpose of this review is to consider and weigh emerging evidence suggesting that, as with neuropathic pain, some anticonvulsant drugs may be effective in reducing postoperative pain. . Selected review articles were used for the discussion of pharmacological mechanisms and selected preclinical studies involving the rat formalin pain model and other studies of interest were used for the discussion of preclinical evidence of analgesic efficacy. All published randomized controlled trials were selected for the discussion of clinical evidence.
Methods

Anticonvulsant drug mechanisms
Anticonvulsant drugs, so defined for their ability to suppress experimental and clinical seizures, have been classified as "first-generation" anticonvulsants (e.g., benzodiazepines, carbamazepine, ethosuximide, phenobarbital, phenytoin, primidone and valproic acid) which were introduced between 1910 and 1970, and "second-generation" anticonvulsants (e.g., felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, vigabatrin and zonisamide) which were introduced more recently. 26 Most anticonvulsant drugs exert multiple pharmacological actions. 27 Anticonvulsant mechanisms which are likely important in the modulation of postoperative pain 28 include sodium channel blockade (e.g., with carbamazepine, felbamate, lamotrigine, oxcarbazepine, phenytoin, topiramate and zonisamide), calcium channel blockade (e.g., with carbamazepine, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, topiramate, valproic acid and zonisamide) and suppression of glutamate release or action on NMDA/AMPA receptors (e.g., with carbamazepine, felbamate, gabapentin, lamotrigine, oxcarbazepine, phenytoin, pregabalin, topiramate and valproic acid), (Figure 1 , Table I ). Although several anticonvulsant drugs potentiate the inhibitory neurotransmitter gamma-amino butyric acid (GABA) which plays a role in pain modulation, 29 analgesic effects of GABAergic anticonvulsants such as benzodiazepines and barbiturates are not reliably observed. 30, 31 Most recognized anticonvulsant mechanisms involve the central nervous system and, indeed, central sensitization is important in postoperative pain. 17 However, the substantial contributions of peripheral tissue inflammation to the pathogenesis of postoperative pain warrants also the consideration of any peripheral mechanisms of anticonvulsant drugs. Of interest, the side effect of gingival hyperplasia with phenytoin has led to extensive laboratory and clinical investigations describing phenytoin's wound healing and anti-inflammatory properties due to a direct effect on tissue fibroblasts. 32 Some clinical studies have suggested that these peripheral effects of phenytoin may also contribute to pain reduction. 33, 34 Peripheral effects of another anticonvulsant were reported in a laboratory study showing that, in addition to analgesia, carbamazepine demonstrates an anti-inflammatory effect as indicated by decreased plasma extravasation, possibly due to reduction of neurogenic inflammation. 35 Finally, it is interesting to observe from rat formalin pain studies, that local injections of gabapentin 36 or lamotrigine 37 exert analgesic effects, suggesting a direct action of these drugs on peripheral neurotransmission.
Preclinical evidence of analgesic efficacy
Although the clinical predictive value of many preclinical pain models is debatable, several features of the biphasic rat formalin pain response are thought to parallel changes seen after surgery. 38 While the first phase of pain behaviour following sc formalin injection has been equated with acute nociception during surgery, the second phase is thought to parallel later expressions of postoperative pain which are sustained by spinal sensitization and possibly by peripheral inflammation. 39 Of relevance to this review, the antinociceptive effects of several anticonvulsants have been evaluated in the rodent formalin pain model (Table I) . While both phases 1 and 2 formalin-induced nociception were shown to be reduced by ethosuximide 40, 41 and vigabatrin, 42 only phase 2 was reduced by carbamazepine, 43 gabapentin, 44 lamotrigine, 45 oxcarbazepine 46 and pregabalin. 44 Equivocal results were reported for tiagabine 41, 45 and valproic acid, 41, 47 possibly due to species differences. Finally, small numbers of studies have reported that benzodiazepines, 48, 49 levetiracetam, 41 phenobarbital, 41 phenytoin, 50 topiramate 41 and zonisamide 41 were ineffective at the doses studied. A more direct approach towards modelling postoperative pain was pursued by Brennan et al. using a true incisional pain model which was shown, as in humans, to result in postoperative hyperalgesia and allodynia. 51 Subsequent studies showed that the anticonvulsant, gabapentin, reduces allodynia and hyperalgesia after plantar incision 52 and thoracotomy in rat models. 53 A more recent study indicated that gabapentin alone was ineffective after rat laparotomy and induction of pancreatitis but that it did enhance opioid efficacy under these conditions. 54 Pregabalin was also shown to reduce allodynia and hyperalgesia after rat plantar incision. 52 A few human preclinical anticonvulsant studies may have relevance to postoperative pain given the nature of the experimental pain stimulus used. For example, gabapentin has been shown to reduce hyperalgesia following heat and topical capsaicin-induced sensitization 55 and also intradermal capsaicin injection 56 while hyperalgesia reduction with gabapentin after experimental first-degree burn failed to reach statistical significance. 57 In the case of lamotrigine, two studies failed to demonstrate any antihyperalgesic effect of this drug following heat and topical capsaicin-induced sensitization 58 or intradermal capsaicin injection.
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Anticonvulsant-opioid interactions and opioid sparing In addition to the limited efficacy of opioids for movement-evoked pain, clinical trials have repeatedly demonstrated that opioids contribute to a wide variety of postoperative adverse effects including respiratory depression, pruritus, nausea, vomiting, ileus, urinary retention, sedation and cognitive dysfunction. 60 In fact, a recent meta-analysis has suggested that postoperative opioid sparing, following NSAID co-administration, in the range of 30-50% leads to reductions in nausea, vomiting and sedation of approximately 30%. 61 While it is unlikely that the analgesic efficacy of any currently available anticonvulsant is sufficient to eliminate the need for postoperative opioids, anti- convulsants may, like NSAIDs, exert an opioid sparing effect. Available evidence suggests that anticonvulsants might decrease opioid consumption either by enhancing opioid analgesia, or by suppressing mechanisms of opioid tolerance or withdrawal. For example, gabapentin has been shown to enhance opioid analgesia in both animal 62 and human 63 models of brief thermal pain as well as in animal 64 and human 65 neuropathic pain. In a cancer pain trial, phenytoin co-administration led to reduced opioid requirements and also gave better pain relief. 66 Various other lines of animal and human evidence suggest further that gabapentin, 67, 68 lamotrigine, 37 writing. All of these trials, as evaluated by the author (I.G.), received a score of at least 2 points (one each for randomization and blinding) on a three-item (1 to 5) quality scale. 92 Following various surgical procedures (Table II) , gabapentin trials have involved single doses varying from 300 mg 76 to 1200 mg 73 administered from 1 to 2.5 hr before surgery. Four multidose trials studied around-the-clock gabapentin administration from one to ten days after surgery. 74, 75, 82, 83 In all but two 75, 87 of the 15 trials, rest pain and opioid consumption were significantly reduced compared to placebo. In all five trials which evaluated movement-related pain, this was also reduced compared to placebo. 73, 74, 80, 82, 83 Most studies reported no significant differences in adverse effects. However, one study reported a slightly higher incidence of sedation with gabapentin following hysterectomy 83 and Pandey et al. reported more sedation and nausea, 76 whereas Turan et al. reported less nausea/vomiting and less urinary retention with gabapentin. 79 While many different doses have been studied, Pandey et al. conducted a dose-response trial of gabapentin single-dose pretreatment in lumbar discectomy patients. These investigators demonstrated an analgesic ceiling effect at a dose of 600 mg, i.e., pain reduction with 600 mg was better than with 300 mg; whereas no additional 1st generation benzodiazepines ----n/a n/a + carbamazepine ++ + + + n/a n/a + ethosuximide -+ ? ++ n/a n/a n/a phenobarbital ----n/a n/a n/a phenytoin ++ ? + -n/a n/a + primidone ----n/a n/a n/a valproic acid ? + + -/+ n/a n/a + 2 nd generation felbamate ++ + + n/a n/a n/a + gabapentin ?
n/a n/a n/a oxcarbazepine ++ + + + n/a n/a n/a pregabalin -+ + + + n/a n/a tiagabine ----/+ n/a n/a n/a topiramate ++ + + -n/a n/a + vigabatrin ---++ n/a n/a n/a zonisamide ++ ++ ? -n/a n/a n/a Modified from reference #27; n/a = no evidence currently available; +/-= equivocal results; ? = currently unclear whether this mechanism is involved.
benefits were observed with doses of 900 or 1200 mg. 85 While most trials evaluated the effects of gabapentin administration before surgery, a recent trial in donor nephrectomy patients showed no difference in pain scores comparing preoperative with post-incisional administration. 86 Three published postoperative trials have compared gabapentin to other drugs. Fassoulaki et al. reported that analgesia and opioid sparing with gabapentin was comparable to that of the sodium channel blocker, mexiletine. 74 Pandey et al. showed that both pain intensity and fentanyl consumption were significantly lower in patients receiving gabapentin before laparoscopic cholecystectomy, compared to those receiving tramadol. 76 Finally, we compared gabapentin to rofecoxib, and these two drugs combined, in patients undergoing hysterectomy. 83 Cumulative postoperative morphine consumption was similarly reduced in both single agent gabapentin and rofecoxib groups, with further significant reductions observed in the combination group. Pain evoked by cough was similar in both gabapentin and rofecoxib groups in this trial.
Secondary benefits
Given that early trials of gabapentin have demonstrated efficacy in the treatment of anxiety, 93, 94 it is interesting to note that one perioperative trial showed an anxiolytic effect with gabapentin after knee surgery. 84 *Approximately equally distributed across all study treatment groups; **Refers only to gabapentin-placebo comparison and refers to pain at rest unless otherwise specified; EMLA = eutectic mixture of local anesthetics; g = gabapentin; ns = not statistically significant; nr = not reported. LA = local anagelsia; PACU = postanesthesia care unit; POD = postoperative day; PCA = patient-controlled analgesia; r = rofecoxib.
In light of previous suggestions that a reduction in movement-evoked pain correlates with improved postoperative function, 95 it is interesting to note that, in the setting of anterior cruciate ligament repair, preoperative gabapentin administration resulted in greater knee flexion angles on postoperative days one and two. 84 Furthermore, we have shown that postoperative pulmonary function, as assessed by peak expiratory flow rate, is improved with both gabapentin and rofecoxib. 83 The combination of these two drugs further enhances this response. 83 Taken together, these results suggest that gabapentin-induced reductions in movement-evoked pain may accelerate postoperative functional recovery. However, future studies with longer follow up are needed in order to determine whether these benefits translate into lower complication rates, earlier hospital discharge, or earlier return to work. Also, given the possibility that more aggressive pain management may prevent chronic post-surgical pain, 96 early evidence that perioperative treatment with gabapentin may reduce chronic postsurgical pain is particularly exciting. 74, 82 Other anticonvulsant medications Few other trials have evaluated anticonvulsant medications for postoperative pain (Table III) , which showed no benefit over placebo, unlike the NSAID, ketoprofen, which was included as an active control. 91 Bonicalzi et al. reported substantial pain reductions with lamotrigine 200 mg for pain after transurethral prostate resection. 88 In 2001, Hill et al. published the first postoperative trial of an alpha-2-delta ligand which involved pregabalin. 90 After oral surgery, pregabalin 300 mg provided a significantly higher pain intensity difference than placebo. 90 The active comparator, ibuprofen 400 mg, showed a trend towards greater peak effect, whereas duration of action was longer with pregabalin. In preliminary abstract form, Sheen et al. recently reported on the analgesic and opioid sparing effects of oxcarbazepine after vaginal hysterectomy. 89 
Safety issues
Given the brief exposure and relatively small numbers of trial patients, it is apparent that the safety evaluation of anticonvulsant drugs administered in the perioperative setting is incomplete. Investigations of gabapentin for treatment of epilepsy and chronic pain suggest that this drug is associated with sedation and ataxia, as relatively common dose-dependent and reversible adverse effects. 97, 98 Less commonly, weight gain and peripheral edema have been reported at gabapentin doses exceeding 1800 mg·day -1 . 97, 98 Clearly, more clinical investigation is required in order to better characterize the specific toxicities of gabapentin and other anticonvulsant drugs in the perioperative setting.
Conclusion
There are many available anticonvulsant drugs whose mechanisms of action may be important in treating post-surgical pain. Specific mechanisms include sodium and calcium channel antagonism, and decreased glutamate transmission. A growing body of preclinical evidence suggests that several anticonvulsant medications are antinociceptive in preclinical models of postoperative pain (e.g., carbamazepine, ethosuximide, gabapentin, lamotrigine, oxcarbazepine, pregabalin, and vigabitrin), and enhance opioid efficacy or suppress opioid analgesic tolerance. Results from recent clinical trials demonstrate analgesic efficacy, opioid sparing effect, and possible postoperative functional improvement associated with gabapentin. Other trials also suggest the potential analgesic efficacy of other anticonvulsant drugs including pregabalin, lamotrigine and possibly oxcarbazepine. Future research is needed to identify anticonvulsant drugs with the best perioperative therapeutic profile and, also, to further explore varying applications of these drugs (e.g., dose, timing, patient populations and co-administration with other non-opioid analgesics) in order to optimize their clinical utility.
